VXRT News and Press, Vaxart Inc. From 08/13/20

NEW YORK , Aug. 13, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make fals...

Now that Vaxart 's (NASDAQ: VXRT) coronavirus vaccine candidate is concluding preclinical development and embarking on the lengthy clinical trial process, the company's chances of success are higher than ever before. While there's still some work to do before the candidate will have a chance ...

Coronavirus-related stocks declined sharply on Wednesday, extending their losses following Russia's announcement on Tuesday that it had developed the world's first COVID-19 vaccine.  As of 11:55 a.m. EDT, shares of Novavax (NASDAQ: NVAX) , Heat Biologics (NASDAQ: HTBX) , Sorrento Th...

The New York Times reports that Russia's President Vladimir Putin is claiming victory in the global race to a COVID-19 vaccine with today's announcement that its home-grown offering, based on two adenovirus strains akin to Oxford University and AstraZeneca's ( AZN +0.2% ) candidate ChA...

SAN DIEGO, CA / ACCESSWIRE / August 11, 2020 / The Shareholders Foundation, Inc. announces that a lawsuit was filed by a current investor in Vaxart, Inc. (NASDAQ:VXRT) shares over alleged breaches of fiduciary duties by certain directors of Vaxart, Inc. Investors, who purchased shares of Va...

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its COVID-19 Investigational New Drug (IND) application has...

Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) have practically become household names in 2020, largely thanks to their efforts to develop vaccines for COVID-19. Both of these companies have also performed exceptionally well on the stock market of late. Year to date, shares of Novavax ...

iBio Pharma (NYSEMKT: IBIO) and Vaxart (NASDAQ: VXRT) rank as two of the biggest winners so far this year among small-cap biotechs with coronavirus programs. Shares of iBio have skyrocketed more than 1,600% year to date, while Vaxart stock is up close to 2,500%. Which of these coronavir...

Vaxart (NASDAQ: VXRT ) : Q2 GAAP EPS of -$0.12 misses by $0.08 . More news on: Vaxart, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Enhanced Leadership – New CEO in Q2 Ample Cash Runway following Financing by Notable Institutional Healthcare Investors SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are ...